HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
复制标题
DOI：
10.1136/gutjnl-2013-305517
复制
发表时间：
2014-08-01
期刊：
影响因子：
24.5
通讯作者：
Suh, Dong Jin
中科院分区：
文献类型：
--
作者：
Kim, Gi-Ae;Lim, Young-Suk;Suh, Dong Jin
目的慢性B型肝炎（CH B）患者核苷（酸）类似物（NUC）治疗后HBsAg血清清除的长期临床结果和持久性尚不清楚。在5409例最初接受拉米夫定或恩替卡韦治疗的CHB患者中，结果基线ALT水平> 5倍正常值上限与HBsAg清除率相关（HR 1.80，p < 0.01），基线ALT水平>5倍正常值上限与HBsAg清除率相关（HR 1.80，p < 0.01），基线ALT水平>5倍正常值上限与HBsAg清除率相关（HR 1.80，p < 0.01），基线ALT水平> 5倍正常值上限与HBsAg清除率相关（HR 1.80，p < 0.01）。
Objective Little is known about the long-term clinical outcome and durability of HBsAg seroclearance following nucleos(t)ide analogue (NUC) therapy in patients with chronic hepatitis B (CHB).Design During a median follow-up period of 6 years (33 567 patient-years) of 5409 CHB patients who were initially treated with lamivudine or entecavir, a total of 110 achieved HBsAg seroclearance (0.33% annual seroclearance rate) and were included in this study.Results Baseline alanine aminotransferase (ALT) level >5 times of upper limit of normal was associated with higher probability of HBsAg seroclearance (HR 1.80, p